U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07267481) titled 'Switching From Xiidra to TRYPTYR' on Nov. 25.
Brief Summary: To determine the efficacy of switching participants who are being treated with Xiidra to acoltremon 0.003%.
Hypothesis: Switching to acoltremon 0.003% will greatly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
Dry Eye
Dry Eyes Chronic
Dry Eye Syndromes
Eye Diseases
Intervention:
DRUG: acoltremon 0.003%
Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated ...